India's Alembic Pharma posts higher Q4 profit on strong N.America sales [Reuters]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Reuters
Consolidated profit rose to 1.78 billion rupees ($21.3 million) in the three months ended March 31, from 1.53 billion rupees a year earlier. Indian generic drugmakers like Dr. Reddy's Laboratories , Cipla and Sun Pharmaceutical have been benefitting from price recovery in the U.S. market as well as strong sales, especially of their copycat versions of Bristol-Myers Squibb's blockbuster cancer drug Revlimid. On Tuesday, Dr Reddy's fourth-quarter profit estimates, boosted by strong U.S. sales of its generic version of Revlimid. Alembic Pharma, which also sells a copycat version of Revlimid, said overall revenue rose nearly 8% to 15.17 billion rupees. Sales in North America grew 19%, while domestic sales climbed 3% in the quarter. India and the U.S. contributed around 61% of the drugmaker's total revenue. ($1 = 83.5000 Indian rupees) Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up Reporting by Kashish Ta
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- US Generic Drug Industry Research 2024-2032: $124 Billion Market Analysis by Segment, Therapy Area, Drug Delivery, & Distribution Channel [Yahoo! Finance]Yahoo! Finance
- Non-Steroidal Anti-Inflammatory Drugs Market Size to Worth USD 33.55 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $80.00 to $81.00. They now have an "overweight" rating on the stock.MarketBeat
RDY
Earnings
- 5/8/24 - Beat
RDY
Sec Filings
- 5/17/24 - Form 6-K
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- RDY's page on the SEC website